106 related articles for article (PubMed ID: 12872613)
21. In vivo evaluation of silybin nanosuspensions targeting liver.
Wang Y; Wang L; Liu Z; Zhang D; Zhang Q
J Biomed Nanotechnol; 2012 Oct; 8(5):760-9. PubMed ID: 22888746
[TBL] [Abstract][Full Text] [Related]
22. A comparative study on the therapeutic effects of silymarin and silymarin-loaded solid lipid nanoparticles on D-GaIN/TNF-α-induced liver damage in Balb/c mice.
Cengiz M; Kutlu HM; Burukoglu DD; Ayhancı A
Food Chem Toxicol; 2015 Mar; 77():93-100. PubMed ID: 25544390
[TBL] [Abstract][Full Text] [Related]
23. Antioxidant and hepatoprotective effects of Ginkgo biloba phytosomes in carbon tetrachloride-induced liver injury in rodents.
Naik SR; Panda VS
Liver Int; 2007 Apr; 27(3):393-9. PubMed ID: 17355462
[TBL] [Abstract][Full Text] [Related]
24. Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles.
Nounou MM; El-Khordagui LK; Khalafallah N
Acta Pol Pharm; 2005; 62(5):369-79. PubMed ID: 16459486
[TBL] [Abstract][Full Text] [Related]
25. Silymarin loaded liposomes for hepatic targeting: in vitro evaluation and HepG2 drug uptake.
Elmowafy M; Viitala T; Ibrahim HM; Abu-Elyazid SK; Samy A; Kassem A; Yliperttula M
Eur J Pharm Sci; 2013 Oct; 50(2):161-71. PubMed ID: 23851081
[TBL] [Abstract][Full Text] [Related]
26. Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice.
Domitrović R; Rashed K; Cvijanović O; Vladimir-Knežević S; Škoda M; Višnić A
Chem Biol Interact; 2015 Mar; 230():21-9. PubMed ID: 25656916
[TBL] [Abstract][Full Text] [Related]
27. Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.
Ruan X; Shen C; Meng Q
Food Chem Toxicol; 2010 May; 48(5):1145-51. PubMed ID: 20138203
[TBL] [Abstract][Full Text] [Related]
28. Development, characterization and in vivo evaluation of benzocaine-loaded liposomes.
Mura P; Maestrelli F; González-Rodríguez ML; Michelacci I; Ghelardini C; Rabasco AM
Eur J Pharm Biopharm; 2007 Aug; 67(1):86-95. PubMed ID: 17350813
[TBL] [Abstract][Full Text] [Related]
29. Polyethylene Sebacate-Silymarin Nanoparticles with Enhanced Hepatoprotective Activity.
Guhagarkar SA; Shah D; Patel MD; Sathaye SS; Devarajan PV
J Nanosci Nanotechnol; 2015 Jun; 15(6):4090-3. PubMed ID: 26369016
[TBL] [Abstract][Full Text] [Related]
30. Hepatoprotective effects of silymarin coated gold nanoparticles in experimental cholestasis.
Clichici S; David L; Moldovan B; Baldea I; Olteanu D; Filip M; Nagy A; Luca V; Crivii C; Mircea P; Katona G; Filip GA
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111117. PubMed ID: 32600716
[TBL] [Abstract][Full Text] [Related]
31. Double-loaded liposomes encapsulating lycopene β-cyclodextrin complexes: preparation, optimization, and evaluation.
Jhan S; Pethe AM
J Liposome Res; 2020 Mar; 30(1):80-92. PubMed ID: 31044628
[TBL] [Abstract][Full Text] [Related]
32. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
33. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin.
Valenzuela A; Garrido A
Biol Res; 1994; 27(2):105-12. PubMed ID: 8640239
[TBL] [Abstract][Full Text] [Related]
34. Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine.
Arulsudar N; Subramanian N; Mishra P; Sharma RK; Murthy RS
J Drug Target; 2003 Apr; 11(3):187-96. PubMed ID: 13129826
[TBL] [Abstract][Full Text] [Related]
35. [The effect of hepatoprotectors on lipid metabolism in CCl4-hepatitis].
Vengerovskiĭ AI; Chuchalin VS; Paul's OV; Saratikov AS
Biull Eksp Biol Med; 1987 Apr; 103(4):430-2. PubMed ID: 3567336
[TBL] [Abstract][Full Text] [Related]
36. Preparation, Characterization and Cytotoxicity of Silibinin- Containing Nanoniosomes in T47D Human Breast Carcinoma Cells.
Amiri B; Ebrahimi-Far M; Saffari Z; Akbarzadeh A; Soleimani E; Chiani M
Asian Pac J Cancer Prev; 2016; 17(8):3835-8. PubMed ID: 27644625
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and antihepatotoxic activity of some heterocyclic compounds containing the 1,4-dioxane ring system.
Ahmed B; Khan SA; Alam T
Pharmazie; 2003 Mar; 58(3):173-6. PubMed ID: 12685811
[TBL] [Abstract][Full Text] [Related]
38. Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin.
Dube D; Khatri K; Goyal AK; Mishra N; Vyas SP
Drug Dev Ind Pharm; 2010 May; 36(5):547-55. PubMed ID: 19895190
[TBL] [Abstract][Full Text] [Related]
39. Dextrose modified bilosomes for peroral delivery: improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats.
Parashar P; Rana P; Dwivedi M; Saraf SA
J Liposome Res; 2019 Sep; 29(3):251-263. PubMed ID: 30501440
[TBL] [Abstract][Full Text] [Related]
40. Design and development of liposomes for colon targeted drug delivery.
Gupta AS; Kshirsagar SJ; Bhalekar MR; Saldanha T
J Drug Target; 2013 Feb; 21(2):146-60. PubMed ID: 23373543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
